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Abstract
Background: In the last ten years, deficiencies in tricarboxylic acid cycle (TCAC) enzymes have been shown to
cause a wide spectrum of human diseases, including malignancies and neurological and cardiac diseases. A
prerequisite to the identification of disease-causing TCAC enzyme deficiencies is the availability of effective enzyme
assays.
Results: We developed three assays that measure the full set of TCAC enzymes. One assay relies on the sequential
addition of reagents to measure succinyl-CoA ligase activity, followed by succinate dehydrogenase, fumarase and,
finally, malate dehydrogenase. Another assay measures the activity of a-ketoglutarate dehydrogenase followed by
aconitase and isocitrate dehydrogenase. The remaining assay measures citrate synthase activity using a standard
procedure. We used these assays successfully on extracts of small numbers of human cells displaying various
severe or partial TCAC deficiencies and on frozen heart homogenates from heterozygous mice harboring an SDHB
gene deletion.
Conclusion: This set of assays is rapid and simple to use and can immediately detect even partial defects, as the
activity of each enzyme can be readily compared with one or more other activities measured in the same sample.
Background
Interest in assaying tricarboxylic acid cycle (TCAC)
enzyme activities has been rek i n d l e db ye v i d e n c et h a t
deficiencies in these enzymes cause a variety of human
diseases [1,2], in contradiction to the long-held belief
that any TCAC enzyme deficiency is lethal [3]. Several
acquired conditions are characterized not only by post-
translational alterations in electron transport respiratory
chain proteins and impairments in mitochondrial cal-
cium handling, but also by abnormalities in TCAC
enzymes. Examples include heart failure in humans [4]
and stress-related heart dysfunction induced in rats by
chronic restraint [5]. Several inherited diseases have
been ascribed to primary TCAC enzyme deficiencies
(Table 1). For instance, primary succinate dehydrogen-
ase (SDH; EC.1.3.99.1) deficiency results either in tissue
degeneration with devastating early-onset encephalo-
myopathy or in tissue proliferation with formation of
paragangliomas or other tumors [2]. Similarly, a
mutation in the gene encoding fumarase (EC. 4.2.1.2) is
a rare cause of encephalomyopathy and a far more com-
mon cause of leiomyomas of the skin and uterus and of
renal cancer [6]. TCAC dysfunction may also result
from concurrent impairments in several steps of the
cycle. For instance, combined deficiencies in SDH and
aconitase (EC. 4.2.1.3) is observed in Friedreich’sa t a x i a
[7].
Residual activities associated with TCAC impairments
in humans vary widely and may determine the magni-
tude of organic acid accumulation [8]. Organic acid
accumulation has been proven instrumental in initiating
tumor formation related to SDH or fumarase deficiency
[9].
The ratios between TCAC enzymes are consistent for
each mammalian tissues presumably reflecting their
metabolic demand, as shown three decades ago in the
seminal study by Pette and Hofer [10]. This echoes the
occurrence of metabolons in the mitochondrial matrix
[11-13], allowing for efficient channeling of substrates
and co-factors through the Krebs cycle and related
enzymes such as transaminase [14]. Consequently, in * Correspondence: pierre.rustin@inserm.fr
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ities, estimation of ratios between enzyme activities is an
effective means of detecting partial but potentially harm-
ful deficiencies. When used to assess respiratory chain
activities, this approach enabled the identification of sev-
eral gene mutations, even in patients with partial
respiratory chain deficiencies [15,16].
At present, TCAC enzyme activities are measured
using a series of independent assays that are both labor-
ious and time consuming. We therefore developed a
limited set of assays allowing both measurement of all
TCAC enzyme activities and detection of abnormalities
in enzyme activity ratios. We used these assays success-
fully to detect severe and partial isolated deficiencies in
several TCAC enzymes.
Results
Given that TCAC enzyme activity ratios, because of
their consistency [17], are important in comparing data
between samples, we devised a method for measuring
the activities of all eight TCAC enzymes using only
three assays, which allows rapid determination of
enzyme activity ratios. To define appropriate assay con-
ditions, we first used mouse heart samples and assessed
various parameters (detergent, pH, ionic force) that are
known to independently stimulate each activity, but
which might interfere with the measurement of other
activities. We found that two media were sufficient for
assaying all TCAC activities. The difference between
these two media lies in the presence of phosphate
required by some of the enzymes and in the use of elec-
tron acceptors to cope with the various reduced
equivalents.
The first assay measures five enzymes sequentially in
an individual sample (Fig. 1A). Importantly, while four
of these enzymes catalyze steps of the TCAC, one,
GDH, is measured as a consequence of the required
presence of glutamate for the assay of MDH. Glutamate
is required for the added aspartate amino transferase
reaction in order to transaminate the oxaloacetate pro-
duced by MDH, which otherwise would rapidly block
this last enzyme (Fig. 1B). The biological sample is first
added to a detergent-containing medium allowing sub-
strates and electron acceptors free access to their
respective binding sites on the proteins. However, we
found that succinyl-CoA batches variably contained
reducing agents capable of interacting with the electron
acceptor mixture used in the assay. Therefore, the assay
is started only after most of this non-enzymatic reaction
is completed. Then, biological sample is added to enable
measurement of the first enzyme, GTP- and/or ATP-
forming succinyl-CoA ligase, based on the amount of
succinate formed by the enzyme. The succinate is then
readily oxidized to fumarate by SDH concomitantly with
ultimate reduction of DCPIP. In this assay, electrons
from succinate are transferred by SDH to either phena-
zine methosulfate or decylubiquinone, both capable of
reducing DCPIP. Maximal SDH activity is then mea-
sured by adding a large amount of succinate. Adding
malonate, a competitive SDH inhibitor, essentially
abolishes DCPIP reduction. Subsequent addition of glu-
tamate, because of the presence of added NAD
+,a l l o w s
estimation of NAD
+-dependent GDH activity. Depend-
ing on the enzyme activity levels in the sample, it may
be necessary at this point to add more DCPIP before
performing the next assays (fumarase and MDH activ-
ity). Fumarase is assayed by adding a large fumarate
excess, which is readily converted to malate by fumar-
ase, this latter acid being used up by MDH to produce
NADH and oxaloacetate. Owing to the presence of
added aspartate aminotransferase and glutamate, oxaloa-
cetate does not accumulate and, therefore, does not
slow the MDH reaction. The last enzyme of the assay,
MDH, is then measured by adding 10 mM malate.
The second assay starts with measurement of the
reduction of pyridine nucleotides (NAD
+/NADP
+)b y
KDH. This enzyme, one of the limiting steps of the
TCAC, requires the presence of Ca
++ ions, thiamine
Table 1 Primary deficiencies in tricarboxylic acid cycle enzymes in humans.
Enzyme
1 Clinical presentation References
Fumarase 1. Progressive encephalopathy
2. Hereditary leiomyomatosis and renal cell cancer
1. [19]
2. [27]
Malate dehydrogenase No disease identified so far
Citrate synthase No disease identified so far
Aconitase No disease identified so far
Isocitrate dehydrogenase Low-grade gliomas [32]
a-ketoglutarate dehydrogenase Congenital lactic acidosis [28]
Succinyl CoA ligase Encephalomyopathy with mtDNA depletion [33]
Succinate dehydrogenase 1. Encephalopathy (Leigh syndrome)
2. Pheochromocytoma and paraganglioma
1. [20]
2. [34]
1 Only primary enzyme deficiencies caused by known gene mutations are indicated, excluding secondary deficiencies that may be from genetic (e.g., Friedreich’s
ataxia with aconitase and succinate dehydrogenase deficiencies) or non genetic origin.
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Page 2 of 8pyrophosphate, and coenzyme A to catalyze the oxida-
tion of a-ketoglutarate. After KDH measurement, cis-
aconitate is added for measurement of aconitase activity
based on the formation of isocitrate, which, in the pre-
sence of IDH, is readily used up to reduce NAD
+/NADP
+.
Finally, the maximal activity rate of IDH is determined
after addition of a large isocitrate excess. Citrate
synthase, the last TCAC enzyme to be measured, con-
denses acetyl-CoA and oxaloacetate into citrate while
concomitantly releasing coenzyme A, whose thiol
residue readily reacts with Ellman’s reagent
(dithionitrobenzene). It is measured using the standard
procedure which, in the case of cultured skin fibroblasts,
concomitantly allows the detection of mycoplasma [18].
Since part of these assays relies on coupling between
several successive enzymes, e.g., aconitase and IDH, we
evaluated the proportionality/linearity of these assays as
a function of protein concentration in heart sample
homogenate (Fig. 2). For protein concentrations of up to
150 μg per ml, each assay exhibited a linear response.
Given that the protein concentration presumably
depends on the extent of mitochondria enrichment in
Figure 1 Tricarboxylic acid cycle enzyme assays. A, The first segment of the tricarboxylic acid cycle can be conveniently evaluated using a
single assay to measure five enzymes by spectrophotometrically recording the reduction of DCPIP. The sequential assay begins by measurement
of succinyl-CoA ligase activity based on oxidation of the produced succinate by succinate dehydrogenase, which forwards the electrons to the
electron acceptors (DQ, DCPIP, and PMS). Coupling of these two activities to estimate succinyl-CoA ligase activity is permitted by the much
higher activity of SDH than of succinyl-CoA ligase. After SDH inhibition by malonate, simultaneous addition of glutamate and aspartate
aminotransferase ensures elimination of any oxaloacetate in the assay medium, thereby allowing further measurement of MDH activity.
Incidentally, the required presence of NAD+ permits the measurement of glutamate dehydrogenase activity. Adding more DCPIP allows
subsequent measurement of fumarase and MDH activity. Again, the coupling assay to estimate fumarase activity using MDH activity is permitted
by the much higher activity of MDH. B, A second spectrophotometric assay subsequently measures pyridine dinucleotide reduction by three
additional enzymes starting with a-ketoglutarate dehydrogenase. The next enzyme to be measured is aconitase, whose product, isocitrate, is
readily oxidized by isocitrate dehydrogenase, producing NADPH. A saturating isocitrate concentration is finally added to enable measurement of
isocitrate dehydrogenase activity. C, respective proportions of TCAC enzyme activities in mouse heart. The inset shows the TCAC depicted as two
interacting enzyme cycles, A and B. Cycle A: a-ketoglutarate dehydrogenase (6), succinyl CoA ligase (1), succinate dehydrogenase (2), fumarase
(4), and malate dehydrogenase (5); Cycle B: citrate synthase (9), aconitase (7), and isocitrate dehydrogenase (8). The two cycles interact via the
activity of aspartate aminotransferase (10).
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before running quantitative assays on any tissue/cell.
Finally, to evaluate the ability of our assays to detect
deficiencies in specific TCAC enzymes, we investigated
an array of samples with previously identified genetic
defects resulting in deficiencies in various TCAC
enzyme activities (Fig. 3). We first studied cultured
human fibroblasts harboring mutations in either the
SDHA or the fumarase gene (patients P1, P2; Fig. 3b, c).
In agreement with our previous studies [19,20], we
found that the SDHA mutation caused an about 60%
decrease, whereas the fumarase gene mutation resulted
in nearly total loss of fumarase activity. Interestingly, the
loss of SDH activity did not hamper our ability to mea-
sure succinyl-CoA ligase activity, which was roughly
similar to the control value. Then, we evaluated whether
our TCAC assay was able to detect partial loss (about
50%) of fumarase activity. We studied a lymphoblastoid
Figure 2 Proportionality between TCAC enzyme activities and protein concentration in mouse heart homogenate.1 - 2 ,4 - 8 :E n z y m e
activities plotted as a function of protein concentration: succinyl-CoA ligase (1), succinate dehydrogenase (2), fumarase (4), malate
dehydrogenase (5), a-ketoglutarate dehydrogenase (6), aconitase (7), and NADP
+/NAD
+-isocitrate dehydrogenase (8). Experimental conditions
were as described in Figure 1. Enzyme numbering according to Figure 1.
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Page 4 of 8cell line from a human patient (P3) harboring a hetero-
zygous mutation in the fumarase gene, previously
shown to result in a nearly complete loss of activity
when associated with a loss of the corresponding allele
in tumors. Again, our assay proved capable of detecting
the predictable partial (~40%) loss of fumarase activity
in these cells, in terms of both the absolute activity and
the activity relative to the other TCAC enzymes in the
sample (Fig, 3d). Finally, heart samples from a mouse
heterozygous for a deleterious mutation in the SDHB
gene (exon 2 deletion) were investigated (Fig. 3e). We
observed a consistent 40% decrease in SDH activity, as
predicted by the heterozygous status of the animal.
Discussion
The renewed interest in measuring TCAC enzyme activity,
shown to be sensitive targets under various pathological
conditions, prompted us to devise a rapid assay method
for detecting TCAC deficiencies in biological samples.
Our previous work on the mitochondrial respiratory chain
established that, in addition to absolute residual activities,
relative ratios of enzyme activities in a metabolic pathway
are effective in detecting even partial deficiencies in a
given enzyme. We therefore developed a set of three
assays that conveniently estimate all TCAC enzyme activ-
ities in tissue homogenates and permeabilized cells.
Although the experimental conditions had to be adapted
to allow for the measurement of many enzymes using a
small number of assays, they were largely based on the
pioneer work done in the 1940s by Krebs and colleagues
[21]. In particular, the concentrations of substrates and
cofactors and the metal requirements for each enzyme
were as determined by these authors.
As a first result of this work, we fully confirmed that
TCAC enzyme activity ratios in each of the different tis-
sues or cell investigated are consistent under basal con-
ditions, as previously observed by Pette and colleagues
as early as 1960[10,22].
To date there has been a lot of efforts to provide con-
venient assay procedures for respiratory chain enzymes
[16,23-25]. In contrast, to our knowledge, there is no
report on any convenient enzymatic procedure to mea-
sure the overall activity of TCAC enzymes in the con-
text of screening procedures. Although our assays are
rapid and sensitive, they have intrinsic limitations. First,
three of the enzymes (succinyl-CoA ligase, fumarase,
and aconitase) are measured via coupled assays invol-
ving the next enzyme in the cycle (SDH, MDH, and
IDH, respectively). Obviously, a severe deficiency in the
next enzyme would impair the ability of the assay to
measure the first enzyme. Therefore, deficiencies in two
consecutive enzymes should be evaluated by assaying
each enzyme activity separately via standard methods.
Second, although our assays are sufficiently sensitive to
detect even partial deficiencies in one TCAC enzyme,
measuring the slower enzymes via coupled assays (e.g.,
aconitase) requires a sample that is large enough to
avoid problems with product dilution (e.g., isocitrate in
the case of aconitase), which would impair the activity
of the coupled enzyme (e.g., IDH in the case of aconi-
tase). Despite these limitations, our set of assays enabled
us to detect all TCAC enzyme deficiencies. Even a 40%
decrease in fumarase activity in lymphoblastoid cell lines
was readily detected.
So far there has been only a limited number of diseases
which have been associated with primary isolated or mul-
tiple defect of the TCAC [7,19,20,26-28]. Beside primary
defects of the TCAC genes, as some of the TCAC proteins
harbor oxygen-sensitive iron-sulfur cluster, i.e. aconitase,
or require a full set of co-factors, i.e. a-ketoglutarate dehy-
drogenase, a loss of activity - secondary but yet possibly
instrumental in the pathophysiological process - might
well be observed in a number of conditions such as aging,
Parkinson’s disease or heart failure.
Methods
Biological samples
Fibroblasts derived from forearm biopsies taken with
informed consent from healthy controls and patients
with TCAC enzyme deficiencies were grown under stan-
dard conditions as described elsewhere [29] and frozen
(-80°C). Before use, cells were resuspended in 1 ml of
medium (A) composed of 0.25 M sucrose, 20 mM Tris
(pH 7.2), 40 mM KCl, 2 mM ethylene glycol tetra acetic
acid (EGTA), 1 mg/ml bovine serum albumin (BSA),
0.01% digitonin (w/v), and 10% Percoll (v/v). After 10
min incubation at ice-melting temperature, the cells
were centrifuged (5 min × 2,300 g), the supernatant dis-
carded, and the pellet washed (5 min × 6000 g)w i t h1
ml of medium A devoid of digitonin and Percoll [30].
Lymphoblasts from patients harboring a deleterious het-
erozygous fumarate hydratase gene mutation (N64T)
were processed similarly to the cultured fibroblasts.
Mouse colony was maintained in accordance with
national and institutional guidelines. Animal procedures
were approved by the ethical review panel of the Robert
Debré Institut, Paris, France. Hearts were obtained from
mice, snap frozen in liquid nitrogen and stored at -80°C.
Frozen tissues were homogenized at ice-melting tem-
perature by hand using a glass-glass potter in medium
(1/10-1/20 v/v) composed of 20 mM Tris (pH 7.2), 0.8
Ms u c r o s e ,4 0m MK C l ,2m ME G T A ,a n d1m g / m l
BSA. Large cell debris was removed by low-speed centri-
fugation (1,500 g for 5 min).
Spectrophotometry
The first assay measures succinyl-CoA ligase, SDH, glu-
tamate dehydrogenase (GDH), fumarase, and malate
dehydrogenase (MDH) (see below; Fig. 1). This assay is
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Page 5 of 8Figure 3 Detection of severe and partial TCAC enzyme deficiencies in various biological samples.A ,s e v e r ee n z y m ed e f i c i e n c i e s .( a )
control fibroblasts; (b) SDHA-mutant fibroblasts homozygous for a deleterious R554W mutation, and (c) fumarase-mutant fibroblasts homozygous
for a deleterious E319Q mutation. Note that only the addition of organic acids and inhibitors is indicated, although the experiments also
involved additions of cations, cofactors, etc, similar to those in Figure 1. B, partial enzyme deficiencies. (a) fumarase-mutant lymphoblasts
heterozygous for an N64T mutation; and (b) heart homogenate from a mutant mouse heterozygous for a deleterious SDHB deletion of exon 2.
Numbers along the traces are nmol/min/mg protein. The shaded areas show the decreases compared to control values. C, Graphical
representation of the values obtained for the various samples investigated. Dark symbols indicated statistically significant deficiencies. Values are
means ± 1 SD. A minimal number of three independent assays (up to ten) were performed to calculate the mean values. Experimental
conditions were as in Figure 1. Abbreviations: P1, patient harboring a homozygous SDHA mutation; P2, patient harboring a homozygous
fumarase mutation; P3 patient harboring a heterozygous mutation; succ, succinate; fum, fumarate.
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Page 6 of 8performed in 400 μl of medium A containing 50 mM
KH2PO4 (pH 7.2) and 1 mg/ml BSA. The reduction of
dichlorophenol indophenol (DCPIP) is measured using
two wavelengths (600 nm and 750 nm) with various
substrates and the electron acceptors decylubiquinone
and phenazine methosulfate. The second assay measures
a-ketoglutarate dehydrogenase (KDH), aconitase, and
isocitrate dehydrogenase (IDG) activities. The same
volume of the same medium is used, and pyridine
nucleotide (NAD
+/NADP
+) reduction is measured with
various substrates using wavelengths of 340 nm and 380
nm. In the third assay, citrate synthase is measured by
monitoring dithionitrobenzene (DTNB; Ellman’s
reagent) reduction at wavelengths of 412 nm and 600
nm as previously described[19]. For this study, all mea-
surements were carried out using a Cary 50 spectro-
photometer (Varian Inc., Palo Alto, CA) equipped with
an 18-cell holder maintained at 37°C. Protein was mea-
sured according to Bradford [31]. All chemicals were of
the highest grade from Sigma Chemical Company (St
Louis, MO).
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